Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT07206056
Registration number
NCT07206056
Ethics application status
Date submitted
17/09/2025
Date registered
3/10/2025
Date last updated
9/10/2026
Titles & IDs
Public title
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Query!
Scientific title
TulmiSTAR-01: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Query!
Additional trial identifiers [1]
0
0
2025-521880-10-00
Query!
Additional trial identifiers [2]
0
0
CDZR123A12107
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
TulmiSTAR-01
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Progressive Metastatic Castrate Resistant Prostate Cancer
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Treatment: Drugs - Tulmimetostat DL1 QD
Treatment: Drugs - Tulmimetostat DL2 QD
Treatment: Drugs - Tulmimetostat DL3 QD
Treatment: Drugs - Tulmimetostat Doses 1 or 2 QD
Treatment: Drugs - Tulmimetostat RP2D QD
Treatment: Drugs - JSB462 Dose 1 QD
Treatment: Drugs - JSB462 Dose 2 QD
Treatment: Drugs - JSB462 QD
Treatment: Drugs - Standard of Care (SoC)
Experimental: Part 1a: Cohort DL1A - Tulmimetostat DL1 QD + JSB462 Dose 1 QD
Experimental: Part 1a: Cohort DL1B - Tulmimetostat DL1 QD + JSB462 Dose 2 QD
Experimental: Part 1a: Cohort DL2A - Tulmimetostat DL2 QD + JSB462 Dose 1 QD
Experimental: Part 1a: Cohort DL2B - Tulmimetostat DL2 QD + JSB462 Dose 2 QD
Experimental: Part 1a: Cohort DL3A - Tulmimetostat DL3 QD + JSB462 Dose 1 QD
Experimental: Part 1a: Cohort DL3B - Tulmimetostat DL3 QD + JSB462 Dose 2 QD
Experimental: Part 1b : Arm A - Tulmimetostat Dose 1 QD + JSB462 QD
Experimental: Part 1b: Arm B - Tulmimetostat Dose 2 QD + JSB462 QD
Experimental: Part 2: Arm 1 - Tulmimetostat RP2D QD + JSB462 QD
Active comparator: Part 2: Arm 2 - Standard of Care at the discretion of the investigator
Treatment: Drugs: Tulmimetostat DL1 QD
Part 1a (dose escalation):
Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))
Treatment: Drugs: Tulmimetostat DL2 QD
Part 1a (dose escalation):
Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))
Treatment: Drugs: Tulmimetostat DL3 QD
Part 1a (dose escalation):
Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))
Treatment: Drugs: Tulmimetostat Doses 1 or 2 QD
Part 1b (dose expansion and optimization):
tulmimetostat doses 1 or 2 QD
Treatment: Drugs: Tulmimetostat RP2D QD
Part 2:
tulmimetostat Recommended Phase 2 Dose (RP2D) QD
Treatment: Drugs: JSB462 Dose 1 QD
JSB462 Dose 1 QD
Treatment: Drugs: JSB462 Dose 2 QD
JSB462 Dose 2 QD
Treatment: Drugs: JSB462 QD
The dose of JSB462 QD will be determined based on the totality of data from Part 1a
Treatment: Drugs: Standard of Care (SoC)
Androgen Receptor Pathway Inhibitors (ARPI), chemotherapy or Pluvicto (AAA617) at the discretion of the investigator
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Description of the comparator or control
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Part 1a: Dose-limiting toxicities (DLTs)
Query!
Assessment method [1]
0
0
A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness/injury, or concomitant medications that occurs within the first 28 days of treatment with tulmimetostat and JSB462 and meets any of the criteria specified in the protocol. The National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) version 5.0 will be used for all grading. For the purpose of dose-escalation decisions, DLTs will be considered and included in the Bayesian Logistic Regression Model (BLRM).
Query!
Timepoint [1]
0
0
Up to 28 days
Query!
Primary outcome [2]
0
0
Part 1a and Part 1b: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [2]
0
0
The analysis of adverse events will include categorization by type, frequency, and severity, as graded by the NCI CTCAE version 5.0.
Query!
Timepoint [2]
0
0
From date of randomization till 30 days safety fup, assessed up to approximately 14 months
Query!
Primary outcome [3]
0
0
Part 1a and Part 1b: Number of Participants with dose adjustments
Query!
Assessment method [3]
0
0
The number of participants with dose adjustments (reductions, interruption, or permanent discontinuation) will be summarized by treatment arm.
Query!
Timepoint [3]
0
0
From date of randomization till 30 days safety fup, assessed up to approximately 14 months
Query!
Primary outcome [4]
0
0
Part 1a and Part 1b: Dose Intensity
Query!
Assessment method [4]
0
0
Dose intensity (computed as the ratio of actual cumulative dose received and actual duration of exposure) and the relative dose intensity (computed as the ratio of dose intensity and planned dose intensity) will be summarized by means of descriptive statistics
Query!
Timepoint [4]
0
0
From date of randomization till 30 days safety fup, assessed up to approximately 14 months
Query!
Primary outcome [5]
0
0
Part 1a and Part 1b: Duration of exposure to each study drug
Query!
Assessment method [5]
0
0
The duration of exposure (in months) to Tulmimetostat and JSB462 (Part 1a and Part 1b) will be summarized by means of descriptive statistics
Query!
Timepoint [5]
0
0
From date of randomization till 30 days safety fup, assessed up to approximately 14 months
Query!
Primary outcome [6]
0
0
Part 1b and Part 2: prostate-specific antigen 50 (PSA50) at Month 6
Query!
Assessment method [6]
0
0
PSA50 is defined as a PSA reduction of at least 50% from baseline at 6 months confirmed by a second PSA measurement = 3 weeks later.
Query!
Timepoint [6]
0
0
Month 6
Query!
Secondary outcome [1]
0
0
Part 1a and Part 1b: Plasma concentrations of tulmimetostat and JSB462
Query!
Assessment method [1]
0
0
Tulmimetostat and JSB462 pharmacokinetic (PK) samples will be obtained and evaluated in all participants at all dose levels by treatment arms
Query!
Timepoint [1]
0
0
Cycle 1-2: Day 1 (predose/0 hour, 1 hour, 2 hours, 4 hours, 6 hours and 8 hours; Tulmimetostat only: 30 minutes and 3 hours). Cycle 1: Day 2 (24 hours), Days 8 and 15 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.
Query!
Secondary outcome [2]
0
0
Part 2: Plasma concentrations of tulmimetostat and JSB462
Query!
Assessment method [2]
0
0
Tulmimetostat and JSB462 pharmacokinetic (PK) samples will be obtained and evaluated in all participants at all dose levels by treatment arms
Query!
Timepoint [2]
0
0
Cycle 1 and 2: Day 1 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.
Query!
Secondary outcome [3]
0
0
Part 1a and Part 1b: AUC of tulmimetostat and JSB462
Query!
Assessment method [3]
0
0
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) and Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) will be listed and summarized using descriptive statistics.
Query!
Timepoint [3]
0
0
Cycle 1-2: Day 1 (predose/0 hour, 1 hour, 2 hours, 4 hours, 6 hours and 8 hours; Tulmimetostat only: 30 minutes and 3 hours). Cycle 1: Day 2 (24 hours), Days 8 and 15 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.
Query!
Secondary outcome [4]
0
0
Part 2: AUC of tulmimetostat and JSB462
Query!
Assessment method [4]
0
0
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) and Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) will be listed and summarized using descriptive statistics.
Query!
Timepoint [4]
0
0
Cycle 1 and 2: Day 1 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.
Query!
Secondary outcome [5]
0
0
Part 1a and Part 1b: Cmax of tulmimetostat and JSB462
Query!
Assessment method [5]
0
0
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Cmax will be listed and summarized using descriptive statistics.
Query!
Timepoint [5]
0
0
Cycle 1-2: Day 1 (predose/0 hour, 1 hour, 2 hours, 4 hours, 6 hours and 8 hours; Tulmimetostat only: 30 minutes and 3 hours). Cycle 1: Day 2 (24 hours), Days 8 and 15 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.
Query!
Secondary outcome [6]
0
0
Part 2: Cmax of tulmimetostat and JSB462
Query!
Assessment method [6]
0
0
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Cmax will be listed and summarized using descriptive statistics.
Query!
Timepoint [6]
0
0
Cycle 1 and 2: Day 1 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.
Query!
Secondary outcome [7]
0
0
Part 1b and Part 2: prostate-specific antigen 50 (PSA50) at 3, 9, and 12 months
Query!
Assessment method [7]
0
0
PSA50 is defined as a PSA reduction of at least 50% from baseline at 3, 9, and 12 months confirmed by a second PSA measurement = 3 weeks later.
Query!
Timepoint [7]
0
0
Month 3, Month 9, Month 12
Query!
Secondary outcome [8]
0
0
Part 1b and Part 2: radiographic progression free survival (rPFS)
Query!
Assessment method [8]
0
0
rPFS is defined as time between randomization and the first occurrence of disease progression as per PCWG3-modified RECIST v1.1 or death due to any cause
Query!
Timepoint [8]
0
0
From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 15 months
Query!
Secondary outcome [9]
0
0
Part 1b and Part 2: overall survival (OS)
Query!
Assessment method [9]
0
0
OS is defined as the time between randomization to date of death due to any cause
Query!
Timepoint [9]
0
0
From date of randomization until date of death from any cause, assessed up to approximately 15 months
Query!
Secondary outcome [10]
0
0
Part 1b and Part 2: objective response (OR)
Query!
Assessment method [10]
0
0
OR is defined as a confirmed complete response (CR) or partial response (PR) per PCWG3-modified RECIST 1.1 as assessed by the investigator
Query!
Timepoint [10]
0
0
From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to approximately 15 months
Query!
Secondary outcome [11]
0
0
Part 1b and Part 2: best overall response (BOR)
Query!
Assessment method [11]
0
0
BOR is defined as the best response per Prostate Cancer Working Group 3 (PCWG3)-modified RECIST 1.1 as assessed by the Investigator
Query!
Timepoint [11]
0
0
From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to approximately 15 months
Query!
Secondary outcome [12]
0
0
Part 1b and Part 2: duration of response (DOR)
Query!
Assessment method [12]
0
0
DOR is defined as time between first documented CR/PR and disease progression or death due to any cause per PCWG3-modified RECIST 1.1 as assessed by the investigator
Query!
Timepoint [12]
0
0
From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to approximately 15 months
Query!
Secondary outcome [13]
0
0
Part 1b and Part 2: time to first symptomatic skeletal event (TTSSE)
Query!
Assessment method [13]
0
0
TTSSE is defined as time from randomization to the first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause, whichever occurs first.
Query!
Timepoint [13]
0
0
From randomization until the first occurrence of a new symptomatic bone fracture, spinal cord compression, tumor-related orthopedic surgery, radiation therapy for bone pain, or death, assessed up to 15 months.
Query!
Secondary outcome [14]
0
0
Part 2: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [14]
0
0
The analysis of adverse events will include categorization by type, frequency, and severity, as graded by the NCI CTCAE version 5.0.
Query!
Timepoint [14]
0
0
From date of randomization till 30 days safety fup, assessed up to approximately 15 months
Query!
Secondary outcome [15]
0
0
Part 2: Number of Participants with dose adjustments
Query!
Assessment method [15]
0
0
The number of participants with dose adjustments (reductions, interruption, or permanent discontinuation) will be summarized by treatment arm.
Query!
Timepoint [15]
0
0
From date of randomization till 30 days safety fup, assessed up to approximately 15 months
Query!
Secondary outcome [16]
0
0
Part 2: Dose Intensity
Query!
Assessment method [16]
0
0
Dose intensity (computed as the ratio of actual cumulative dose received and actual duration of exposure) and the relative dose intensity (computed as the ratio of dose intensity and planned dose intensity) will be summarized by means of descriptive statistics
Query!
Timepoint [16]
0
0
From date of randomization till 30 days safety fup, assessed up to approximately 15 months
Query!
Secondary outcome [17]
0
0
Part 2: Duration of exposure to each study drug
Query!
Assessment method [17]
0
0
The duration of exposure (in months) to Tulmimetostat and JSB462 / Standard of Care (SoC) of investigator's choice (Part 2) will be summarized within each strata by means of descriptive statistics
Query!
Timepoint [17]
0
0
From date of randomization till 30 days safety fup, assessed up to approximately 15 months
Query!
Eligibility
Key inclusion criteria
Key
* Participant is an adult man = 18 years of age.
* Participant must have histologically and/or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine or small cell features (current or prior biopsy of the prostate and/or metastatic site).
* Participant must have = 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained = 28 days prior to start of treatment (Part 1a dose escalation) or randomization (Part 1b dose expansion and Part 2).
* Participant must have progressive mCRPC.
* Participant must have a castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L).
* Prior ARPI therapy:
* Part 1a and 1b only: must have progressed on at least one prior second generation ARPI (abiraterone, enzalutamide, darolutamide, or apalutamide).
* Part 2 only: must have progressed on one prior second generation ARPI (abiraterone, enzalutamide, darolutamide, or apalutamide).
* Prior chemotherapy:
* Part 1a dose escalation only: may have received = 2 prior lines of chemotherapy in CRPC setting. Note: Prior chemotherapy is permitted in the HSPC setting.
* Part 1b dose expansion/optimization only: may have received up to one prior line of chemotherapy in CRPC setting. Note: Prior chemotherapy is permitted in the HSPC setting.
* Part 2 only: Participants must be taxane-naïve in mCRPC setting; prior chemotherapy permitted in HSPC setting only
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Males
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
* Previous treatment with any PRC2 inhibitor, including but not limited to EZH2 inhibitors, EZH2/1 inhibitors, or embryonic ectoderm development (EED) inhibitors.
* Previous treatment with a protein degrader compound that targets the AR.
* Known hypersensitivity or contraindication to any of the study treatment components or its excipients or to drugs of similar chemical classes.
* Treatment with any investigational agent within 28 days (or 5 half-lives, whichever is longer) prior to study entry.
* Previous treatment with radioligand therapy in the mCRPC setting, except in Part 1a where participants may have received RLT in mCRPC setting.
* Participants with evidence of mCRPC or biochemical recurrence / PSA only disease or asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy and with normal PSA for = 1 year prior to study entry.
* Participants with a history of CNS metastases must have received therapy (surgery, radiotherapy, gamma knife) and be neurologically stable, asymptomatic, and not receiving corticosteroids for the purpose of maintaining neurologic integrity. Those with leptomeningeal disease are eligible if those areas have been treated, are stable, and no neurological impairment is present. For those with parenchymal CNS metastasis (or a history of CNS metastasis), baseline and subsequent radiological imaging must include evaluation of the brain with MRI (preferred) or CT with contrast.
Other protocol-defined inclusion/exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
15/10/2025
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/12/2030
Query!
Actual
Query!
Sample size
Target
188
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - St Leonards
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Melbourne
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - Liverpool
Query!
Recruitment postcode(s) [1]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [2]
0
0
3000 - Melbourne
Query!
Recruitment postcode(s) [3]
0
0
2170 - Liverpool
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Colorado
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Kansas
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
North Carolina
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Ohio
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Washington
Query!
Country [9]
0
0
Canada
Query!
State/province [9]
0
0
Nova Scotia
Query!
Country [10]
0
0
China
Query!
State/province [10]
0
0
Beijing
Query!
Country [11]
0
0
Denmark
Query!
State/province [11]
0
0
Herlev
Query!
Country [12]
0
0
Denmark
Query!
State/province [12]
0
0
Odense C
Query!
Country [13]
0
0
Denmark
Query!
State/province [13]
0
0
Vejle
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Bordeaux
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Paris
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
North Rhine-Westphalia
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Thuringia
Query!
Country [18]
0
0
Italy
Query!
State/province [18]
0
0
MI
Query!
Country [19]
0
0
Italy
Query!
State/province [19]
0
0
PD
Query!
Country [20]
0
0
Italy
Query!
State/province [20]
0
0
TO
Query!
Country [21]
0
0
Malaysia
Query!
State/province [21]
0
0
Sarawak
Query!
Country [22]
0
0
Mexico
Query!
State/province [22]
0
0
Mexico City
Query!
Country [23]
0
0
Poland
Query!
State/province [23]
0
0
Poznan
Query!
Country [24]
0
0
Singapore
Query!
State/province [24]
0
0
Singapore
Query!
Country [25]
0
0
Spain
Query!
State/province [25]
0
0
A Coruna
Query!
Country [26]
0
0
Spain
Query!
State/province [26]
0
0
Barcelona
Query!
Country [27]
0
0
Spain
Query!
State/province [27]
0
0
Madrid
Query!
Country [28]
0
0
United Kingdom
Query!
State/province [28]
0
0
Surrey
Query!
Country [29]
0
0
United Kingdom
Query!
State/province [29]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).
Query!
Trial website
https://clinicaltrials.gov/study/NCT07206056
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-888-669-6682
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT07206056
Download to PDF